摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(E)-2-(2-hydroxystyryl)quinolin-8-ol | 440359-91-1

中文名称
——
中文别名
——
英文名称
(E)-2-(2-hydroxystyryl)quinolin-8-ol
英文别名
2-[(E)-2-(2-hydroxyphenyl)ethenyl]quinolin-8-ol
(E)-2-(2-hydroxystyryl)quinolin-8-ol化学式
CAS
440359-91-1
化学式
C17H13NO2
mdl
——
分子量
263.296
InChiKey
ZYOPSESPYSZRDP-CSKARUKUSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.8
  • 重原子数:
    20
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    53.4
  • 氢给体数:
    2
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    (E)-2-(2-(8-acetoxyquinolin-2-yl)vinyl)phenyl acetate 在 盐酸 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 3.0h, 以82%的产率得到(E)-2-(2-hydroxystyryl)quinolin-8-ol
    参考文献:
    名称:
    New multi-target-directed small molecules against Alzheimer's disease: a combination of resveratrol and clioquinol
    摘要:
    阿尔茨海默病(AD)是目前治疗上最为困难和最具挑战性的疾病之一。结合白藜芦醇和氯碘羟喹的药效团,基于“多靶点导向的配体”(MTDLs)策略,我们设计并合成了一系列新的AD治疗药物。生物活性测试结果表明,这些化合物具有优异的MTDL特性:显著的自发β-淀粉样蛋白(Aβ)聚集抑制能力和铜(II)诱导的Aβ聚集抑制能力,潜在的抗氧化行为(ORAC-FL值为0.9–3.2 Trolox当量)和生物金属螯合作用。在这些化合物中,(E)-5-(4-羟基苯乙烯基)喹啉-8-醇(10c)表现出最强的自发性Aβ聚集抑制能力(IC50 = 8.50 μM)和铜(II)诱导的Aβ聚集抑制能力,以及分解自发和铜(II)诱导的Aβ聚集产生的结构良好的Aβ纤维的能力。需要注意的是,10c还能通过金属配位作用阻止铜的氧化还原循环,从而控制Cu(I/II)触发的羟基自由基(OH·)生成,这一点通过Cu–抗坏血酸盐氧化还原体系检测得到证实。重要的是,在小鼠中,10c在高达2000 mg kg^-1的剂量下未显示急性毒性,并且能够穿过血脑屏障(BBB),这一点通过平行人工膜渗透检测得到证实。这些结果表明,化合物10c是一种有前景的多功能化合物,可用于开发新型AD药物。
    DOI:
    10.1039/c4ob00998c
点击查看最新优质反应信息

文献信息

  • The solvatochromism and electronic structure of(E)-2-(2-hydroxystyryl)quinolin-8-ol
    作者:Ayşegül GÜMÜŞ、Yadigar GÜLSEVEN SIDIR、İsa SIDIR、Selçuk GÜMÜŞ
    DOI:10.3906/kim-1903-36
    日期:——
    The (E)-2-(2-hydroxystyryl)quinolin-8-ol (abbreviated as HSQ) molecule was synthesized and characterized. The ESIPT, solvatochromism properties, electronic structure, and ground and excited electric dipole moments of this molecule were measured using absorption and fluorescence spectra recorded in 13 different solvents. Its electronic structure via electronic transitions was investigated to find the quantitative values of solvatochromism properties by LSER calculations. The ESIPT mechanism was clarified; ground and excited dipole moments were determined using solvatochromic shift methods. The DFT (B3LYP)/6-311$++$G(d,p) method and basis set with potential energy surface (PES) calculations of proton transfer were used to explain the ESIPT mechanism. NBO analysis, NLO properties, and behavior under an electric field were also determined.
    (E)-2-(2-羟基苯乙烯基)喹啉-8-醇(简称HSQ)分子被合成并进行了表征。利用在13种不同溶剂中记录的吸收和荧光光谱测量了该分子的ESIPT、溶剂色性、电子结构以及基态和激发态电偶极矩。通过电子跃迁研究了其电子结构,并通过LSER计算找到了溶剂色性性质的定量值。ESIPT机理得到了澄清;利用溶剂色性位移法确定了基态和激发态偶极矩。利用DFT(B3LYP)/6-311$++$G(d,p)方法和基态集与势能面(PES)计算质子转移来解释ESIPT机理。还确定了NBO分析、NLO性质和电场下的行为。
  • New multi-target-directed small molecules against Alzheimer's disease: a combination of resveratrol and clioquinol
    作者:Fei Mao、Jun Yan、Jianheng Li、Xian Jia、Hui Miao、Yang Sun、Ling Huang、Xingshu Li
    DOI:10.1039/c4ob00998c
    日期:——
    Alzheimer's disease (AD) is currently one of the most difficult and challenging diseases to treat. Based on the ‘multi-target-directed ligands’ (MTDLs) strategy, we designed and synthesised a series of new compounds against AD by combining the pharmacophores of resveratrol and clioquinol. The results of biological activity tests showed that the hybrids exhibited excellent MTDL properties: a significant ability to inhibit self-induced β-amyloid (Aβ) aggregation and copper(II)-induced Aβ aggregation, potential antioxidant behaviour (ORAC-FL value of 0.9–3.2 Trolox equivalents) and biometal chelation. Among these compounds, (E)-5-(4-hydroxystyryl)quinoline-8-ol (10c) showed the most potent ability to inhibit self-induced Aβ aggregation (IC50 = 8.50 μM) and copper(II)-induced Aβ aggregation and to disassemble the well-structured Aβ fibrils generated by self- and copper(II)-induced Aβ aggregation. Note that 10c could also control Cu(I/II)-triggered hydroxyl radical (OH˙) production by halting copper redox cycling via metal complexation, as confirmed by a Cu–ascorbate redox system assay. Importantly, 10c did not show acute toxicity in mice at doses of up to 2000 mg kg−1 and was able to cross the blood–brain barrier (BBB), according to a parallel artificial membrane permeation assay. These results indicate that compound 10c is a promising multifunctional compound for the development of novel drugs for AD.
    阿尔茨海默病(AD)是目前治疗上最为困难和最具挑战性的疾病之一。结合白藜芦醇和氯碘羟喹的药效团,基于“多靶点导向的配体”(MTDLs)策略,我们设计并合成了一系列新的AD治疗药物。生物活性测试结果表明,这些化合物具有优异的MTDL特性:显著的自发β-淀粉样蛋白(Aβ)聚集抑制能力和铜(II)诱导的Aβ聚集抑制能力,潜在的抗氧化行为(ORAC-FL值为0.9–3.2 Trolox当量)和生物金属螯合作用。在这些化合物中,(E)-5-(4-羟基苯乙烯基)喹啉-8-醇(10c)表现出最强的自发性Aβ聚集抑制能力(IC50 = 8.50 μM)和铜(II)诱导的Aβ聚集抑制能力,以及分解自发和铜(II)诱导的Aβ聚集产生的结构良好的Aβ纤维的能力。需要注意的是,10c还能通过金属配位作用阻止铜的氧化还原循环,从而控制Cu(I/II)触发的羟基自由基(OH·)生成,这一点通过Cu–抗坏血酸盐氧化还原体系检测得到证实。重要的是,在小鼠中,10c在高达2000 mg kg^-1的剂量下未显示急性毒性,并且能够穿过血脑屏障(BBB),这一点通过平行人工膜渗透检测得到证实。这些结果表明,化合物10c是一种有前景的多功能化合物,可用于开发新型AD药物。
查看更多